Cellectar Biosciences (CLRB) Competitors $0.36 0.00 (-0.99%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.50%) As of 03/27/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. QNCX, UNCY, CUE, MRSN, IOBT, ACHL, OPTN, VOR, KRON, and STTKShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Quince Therapeutics (QNCX), Unicycive Therapeutics (UNCY), Cue Biopharma (CUE), Mersana Therapeutics (MRSN), IO Biotech (IOBT), Achilles Therapeutics (ACHL), OptiNose (OPTN), Vor Biopharma (VOR), Kronos Bio (KRON), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Quince Therapeutics Unicycive Therapeutics Cue Biopharma Mersana Therapeutics IO Biotech Achilles Therapeutics OptiNose Vor Biopharma Kronos Bio Shattuck Labs Cellectar Biosciences (NASDAQ:CLRB) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability. Is CLRB or QNCX more profitable? Cellectar Biosciences' return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A N/A -191.22% Quince Therapeutics N/A -53.27%-22.73% Does the media refer more to CLRB or QNCX? In the previous week, Quince Therapeutics had 13 more articles in the media than Cellectar Biosciences. MarketBeat recorded 16 mentions for Quince Therapeutics and 3 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.47 beat Quince Therapeutics' score of 0.10 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CLRB or QNCX? Cellectar Biosciences presently has a consensus target price of $17.67, indicating a potential upside of 4,804.68%. Quince Therapeutics has a consensus target price of $8.00, indicating a potential upside of 471.43%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Does the MarketBeat Community prefer CLRB or QNCX? Cellectar Biosciences received 234 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 54.24% of users gave Cellectar Biosciences an outperform vote. CompanyUnderperformOutperformCellectar BiosciencesOutperform Votes24354.24% Underperform Votes20545.76% Quince TherapeuticsOutperform Votes9100.00% Underperform VotesNo Votes Do institutionals & insiders hold more shares of CLRB or QNCX? 16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 3.7% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CLRB or QNCX? Quince Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$42.77M-$1.33-0.27Quince TherapeuticsN/AN/A-$31.39M-$1.31-1.07 Which has more risk & volatility, CLRB or QNCX? Cellectar Biosciences has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. SummaryQuince Therapeutics beats Cellectar Biosciences on 10 of the 16 factors compared between the two stocks. Remove Ads Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.60M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.217.2023.1319.03Price / SalesN/A226.00383.8993.17Price / CashN/A65.6738.1634.64Price / Book-0.386.476.944.33Net Income-$42.77M$141.90M$3.20B$247.06M7 Day Performance-5.24%-3.05%-2.32%-0.53%1 Month Performance25.29%-4.63%3.07%-3.74%1 Year Performance-90.09%-8.61%11.16%1.72% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.1113 of 5 stars$0.36-1.0%$12.50+3,370.3%-90.1%$16.60MN/A-0.2110Analyst ForecastShort Interest ↑Gap UpQNCXQuince Therapeutics2.3343 of 5 stars$1.38-4.2%$9.50+588.4%+23.9%$60.72MN/A-1.1160Earnings ReportAnalyst ForecastShort Interest ↓News CoveragePositive NewsUNCYUnicycive Therapeutics2.814 of 5 stars$0.58-0.7%$5.33+818.0%-57.1%$60.31M$680,000.00-0.609CUECue Biopharma4.4831 of 5 stars$0.95-0.7%$4.75+400.0%-45.7%$60.18M$9.53M-1.0660Positive NewsMRSNMersana Therapeutics4.4186 of 5 stars$0.48+3.0%$4.25+787.3%-91.7%$59.70M$40.50M-0.79150Short Interest ↓Positive NewsIOBTIO Biotech2.6706 of 5 stars$0.90+2.4%$9.33+937.0%-32.9%$59.29MN/A-0.6630Short Interest ↑Gap UpACHLAchilles Therapeutics2.9578 of 5 stars$1.44+0.7%$4.00+177.8%N/A$59.18MN/A-0.87250Upcoming EarningsNews CoverageOPTNOptiNose2.7057 of 5 stars$5.88+9.7%$16.67+183.4%-58.8%$59.15M$75.67M-1.40190Earnings ReportVORVor Biopharma2.454 of 5 stars$0.86-3.9%$11.36+1,220.1%-65.3%$59.08MN/A-0.52140KRONKronos Bio3.657 of 5 stars$0.95+0.9%$1.63+71.3%-33.5%$57.25M$9.86M-0.66100Short Interest ↓STTKShattuck Labs2.6008 of 5 stars$1.17-1.7%$7.50+541.0%-87.3%$55.86M$6.44M-0.76100Earnings ReportAnalyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies QNCX Alternatives UNCY Alternatives CUE Alternatives MRSN Alternatives IOBT Alternatives ACHL Alternatives OPTN Alternatives VOR Alternatives KRON Alternatives STTK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLRB Stock Free CLRB Stock Alerts